These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 17164995)
1. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. Torikai E; Kageyama Y; Takahashi M; Nagano A Mod Rheumatol; 2006; 16(6):350-4. PubMed ID: 17164995 [TBL] [Abstract][Full Text] [Related]
2. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492 [TBL] [Abstract][Full Text] [Related]
3. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381 [TBL] [Abstract][Full Text] [Related]
4. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Garnero P; Thompson E; Woodworth T; Smolen JS Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425 [TBL] [Abstract][Full Text] [Related]
5. Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis. El Miedany YM; Abubakr IH; El Baddini M J Rheumatol; 1998 Nov; 25(11):2083-7. PubMed ID: 9818648 [TBL] [Abstract][Full Text] [Related]
6. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. Verhoeven AC; Boers M; te Koppele JM; van der Laan WH; Markusse HM; Geusens P; van der Linden S Rheumatology (Oxford); 2001 Nov; 40(11):1231-7. PubMed ID: 11709606 [TBL] [Abstract][Full Text] [Related]
7. Urinary cross-linked N-telopeptides of type I collagen levels in patients with rheumatoid arthritis. Iwamoto J; Takeda T; Ichimura S Calcif Tissue Int; 2003 Apr; 72(4):491-7. PubMed ID: 12574873 [TBL] [Abstract][Full Text] [Related]
8. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Yasunori K; Masaaki T; Tetsuyuki N; Hayato K; Akira N Clin Rheumatol; 2008 Sep; 27(9):1093-101. PubMed ID: 18338203 [TBL] [Abstract][Full Text] [Related]
9. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953 [TBL] [Abstract][Full Text] [Related]
10. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429 [TBL] [Abstract][Full Text] [Related]
11. In long-term bedridden elderly patients with dietary copper deficiency, biochemical markers of bone resorption are increased with copper supplementation during 12 weeks. Kawada E; Moridaira K; Itoh K; Hoshino A; Tamura J; Morita T Ann Nutr Metab; 2006; 50(5):420-4. PubMed ID: 16847394 [TBL] [Abstract][Full Text] [Related]
12. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Wang X; Ma C; Li P; Zhao F; Bi L Clin Rheumatol; 2017 Jun; 36(6):1369-1377. PubMed ID: 28474138 [TBL] [Abstract][Full Text] [Related]
13. Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Koike T; Nakamura H Osteoporos Int; 2016 Feb; 27(2):729-35. PubMed ID: 26294294 [TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038 [TBL] [Abstract][Full Text] [Related]
15. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats. DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950 [TBL] [Abstract][Full Text] [Related]
16. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Lems WF; Gerrits MI; Jacobs JW; van Vugt RM; van Rijn HJ; Bijlsma JW Ann Rheum Dis; 1996 May; 55(5):288-93. PubMed ID: 8660101 [TBL] [Abstract][Full Text] [Related]
17. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538 [TBL] [Abstract][Full Text] [Related]
19. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169 [TBL] [Abstract][Full Text] [Related]
20. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures. Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]